{"id":534914,"date":"2026-06-14T15:06:11","date_gmt":"2026-06-14T15:06:11","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/534914\/"},"modified":"2026-06-14T15:06:11","modified_gmt":"2026-06-14T15:06:11","slug":"ai-model-could-improve-screening-for-primary-aldosteronism","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/534914\/","title":{"rendered":"AI model could improve screening for primary aldosteronism"},"content":{"rendered":"<p>A study of a new AI model examining 30 years of routine electronic health records (EHR) data could improve screening for primary aldosteronism, a leading cause of high blood pressure that is often unrecognized but increases patients&#8217; risk of cardiovascular complications, according to a study being presented Saturday at ENDO 2026, the Endocrine Society&#8217;s annual meeting in Chicago, Ill.<\/p>\n<p>Primary aldosteronism occurs when the adrenal glands-the small glands located on the top of each kidney-produce too much of the hormone aldosterone. This causes aldosterone, which helps balance levels of sodium and potassium, to build up in the body. People with primary aldosteronism face a higher risk of cardiovascular disease than those with primary hypertension.<\/p>\n<p>The true prevalence of primary aldosteronism is unknown, but it is estimated that up to 20 percent of patients with hypertension have primary aldosteronism, according to the study&#8217;s lead researcher, Frank Lee, M.D., of Mayo Clinic in Rochester, Minn. Because effective treatments exist for primary aldosteronism, early diagnosis can prevent future complications and reduce healthcare costs, Lee explained.<\/p>\n<p>The Endocrine Society&#8217;s &#8220;Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline&#8221; released in 2025 calls for more widespread screening for primary aldosteronism. This cause of high blood pressure increases patients&#8217; risk of cardiovascular complications, including stroke, coronary artery disease, atrial fibrillation, heart failure, and renal disease.<\/p>\n<p>Using de-identified data from more than 22,000 patients collected between 1986 and 2025 in the Mayo Clinic Platform-a federated, privacy-preserving infrastructure with multimodal clinical data &#8211; researchers developed an AI screening model that analyzed variables including age, gender, hypertension- and hypokalemia-related ICD diagnoses, systolic blood pressure measurements, potassium blood levels, and prescribed antihypertensive or potassium supplement medications. They then tested it on data of 225,887 adults with hypertension. A XGBoost architecture, a type of machine learning library, predicted patients at risk for primary aldosteronism 12 months prior to diagnosis.<\/p>\n<p>The model showed an AI-based approach to screen for primary aldosteronism may be feasible, Lee said. When researchers set the threshold to identify people at low risk, the model correctly flagged more than 90% of primary aldosteronism cases while missing fewer than 10%. At this setting, about two-thirds of the study participants were identified as candidates for screening.<\/p>\n<blockquote><p>&#13;<\/p>\n<p>During testing on patients with high blood pressure who had never been screened previously for primary aldosteronism, our model identified approximately two out of every three patients for further work-up. Clinicians have been challenged to screen primary aldosteronism effectively. The tool developed by our team could offer a solution based on routine information available in a patient&#8217;s medical records.&#8221;<\/p>\n<p>&#13;<br \/>\n&#13;<\/p>\n<p style=\"text-align: right;\">Frank Lee, M.D., of Mayo Clinic in Rochester, Minn.<\/p>\n<p>&#13;\n<\/p><\/blockquote>\n","protected":false},"excerpt":{"rendered":"A study of a new AI model examining 30 years of routine electronic health records (EHR) data could&hellip;\n","protected":false},"author":2,"featured_media":44438,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[78],"tags":[26692,90,157,4094,18,165,135,1693,10536,19,17,10345,33371,172],"class_list":["post-534914","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-aldosterone","tag-blood","tag-blood-pressure","tag-cardiovascular-disease","tag-eire","tag-endocrine","tag-health","tag-high-blood-pressure","tag-hormone","tag-ie","tag-ireland","tag-kidney","tag-potassium","tag-research"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116749086683553371","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/534914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=534914"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/534914\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/44438"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=534914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=534914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=534914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}